DAB2IP and prostate carcinoma: Since strong evidence indicates that DAB2IP reactivation in prostate cancer counteracts metastasis and chemoresistance [15,16], we chose to edit PC3 and DU145 human prostate cancer cell lines; the two lines differ in DAB2IP expression levels, p53 status, and overall aggressiveness, rendering them suitable for exploring various mechanisms of DAB2IP regulation in cancer.